Alex Hoover

Model-Predicted Fludarabine Exposure and Outcomes after Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Susie Long, Veronika Bachanova, Qing Cao, Christen L. Ebens et autres

us (code pays fourni par la source)

Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy

Regina M. Myers, Yimei Li, Hongyan Liu, Alex Hoover et autres

Abstract INTRODUCTION Outcomes for 1st relapse of pediatric B-lymphoblastic leukemia (B-ALL), especially high/intermediate-risk (HR/IR) relapse, remain unacceptably poor. Limited enrollment of this population on cooperative group clinical trials has impeded our ability to study potentially effective regimens. In the current era, patients …

us, gb, es, au (code pays fourni par la source)

Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study

Abigale Berry, Caitlin W. Elgarten, Yimei Li, Hongyan Liu et autres

Abstract Introduction Pronounced disparities in pediatric B-lymphoblastic leukemia (B-ALL) outcomes by race and ethnicity persist in the contemporary era. Gaps in overall survival (OS) from initial diagnosis are wider than event-free survival, suggesting that post-relapse mechanisms may contribute. However, data on treatment …

us, gb, fr (code pays fourni par la source)

Impact of pre-transplant chemotherapy cycles on allogeneic hematopoietic cell transplant outcomes in pediatric acute myeloid leukemia

Aaron Ackerman, Ryan Shanley, Christen L. Ebens, Troy C. Lund et autres

Abstract Introduction Allogeneic hematopoietic cell transplant (HCT) improves the outcomes of pediatric patients with high-risk acute myeloid leukemia (AML) in first complete remission (CR1). Improved cytogenetic and molecular profiling of AML and data from sequential Children's Oncology Group (COG) trials have enabled …

us (code pays fourni par la source)

Optimizing fludarabine exposure using pharmacokinetic modeling in pediatric patients receiving tisagenlecleucel: A step toward personalized lymphodepletion

Veronika Bachanová, Qing Cao, Christen L. Ebens, Troy C. Lund et autres

Abstract Introduction Tisagenlecleucel (tisa-cel), a CD19-directed CAR T-cell therapy, has transformed therapy in relapsed/refractory pediatric B-cell acute lymphoblastic leukemia. Over 80% of patients will achieve a complete remission after tisa-cel, however 40–50% of responders relapse within a year. Lymphodepleting chemotherapy with fludarabine …

us (code pays fourni par la source)

Survival after first relapse of pediatric B-ALL differs by insurance type: A real-world analysis from the recall-1 study

Katherine Lind, Abigale Berry, Yimei Li, Hongyan Liu et autres

Abstract BACKGROUND Children exposed to poverty during frontline therapy for B-lymphoblastic leukemia (B-ALL) experience inferior overall survival (OS), higher relapse rates, and earlier relapse than their peers. Real-world data describing treatment patterns and survival after relapse of B-ALL are lacking and, as …

us, gb (code pays fourni par la source)

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel

Lauren Appell, Christina Baggott, Khanh Nguyen, Snehit Prabhu et autres

us, qa (code pays fourni par la source)

Multifocal Kaposiform Hemangioendothelioma Successfully Treated With Sirolimus Monotherapy

Matthew J. Mahoney, Daniel D. Miller, Erin P. Fritz, Emily Greengard et autres

Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that typically presents in infancy and may be associated with the Kasabach-Merritt phenomenon (KMP). We present a challenging case of multifocal KHE on the leg of an infant, initially suspected at birth to be …

us (code pays fourni par la source)

Major Adverse Events With Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation

Florian Merkle, Marketa Dimitrov, Svatava Merkle, Alex Hoover et autres

With continued advances in targeted cancer treatment, such as chimeric antigen receptor T-cell (CAR-T) therapy, emergency departments (EDs) across the United States should be prepared to diagnose and care for patients who experience unique adverse events related to CAR-T administration. CAR-T therapy …

us (code pays fourni par la source)

Multifocal Kaposiform Hemangioendothelioma Successfully Treated With Sirolimus Monotherapy

Matthew J. Mahoney, Erin P. Fritz, Alex Hoover, Emily Greengard et autres

Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that typically presents in infancy and may be associated with the Kasabach-Merritt phenomenon (KMP). We present a challenging case of multifocal KHE on the leg of an infant, initially suspected at birth to be …

us (code pays fourni par la source)

Enabling Targeted Drug Delivery for Treatment of Ulcerative Colitis with Mucosal‐Adhesive Photoreactive Hydrogel

Wu Wen, Jian Zhang, Xiao Qu, Ting Chen et autres

Ulcerative colitis (UC) is a chronic inflammatory bowel disease. UC treatments are limited by significant adverse effects associated with non-specific drug delivery, such as systematic inhibition of the host immune system. Endoscopic delivery of a synthetic hydrogel material with biocompatible gelation that …

cn, us (code pays fourni par la source)

Outcomes of Third Allogeneic Hematopoietic Cell Transplantation in Children

Smitha Hosahalli Vasanna, Ryan Shanley, Alex Hoover, Troy C. Lund

Introduction The feasibility and utility of a third allogeneic hematopoietic cell transplant (allo HCT3) are not well understood. Despite improvements in HCT outcomes, some patients still experience failure after the first (HCT1) and second (HCT2) transplants due to graft rejection , graft …

us (code pays fourni par la source)